Nanocarrier-mediated CRISPR/Cas9 Gene Editing of BMP2 for Bone Repair

Year : 2025 | Volume : 03 | Issue : 01 | Page : 14 21
    By

    Divya Saini,

  1. MTech Student, Biomechanics and Simulation Lab, Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Assam, India

Abstract

The growth factor that plays an important role in the formation and repair of bones is bone morphogenetic protein 2(BMP2). Nevertheless, because BMP2 is rapidly degrading and has less than half the time to live, its delivery into bone defects may be difficult. A plan to develop a nanocarrier via CRISPRCas9 gene editing mechanism for the delivery of BMP2 into bone defects is outlined in this research proposal. The system will use nanoparticles to encapsulate the CRISPR/Cas9 components and BMP2 gene and will target the delivery of the system to bone-forming cells. BMP2 clinical use is impeded by fast degradation of in vivo, which limits efficacy to a shorter period of time. In order to address these problems a new nanocarrier mediated, CRISPRCas9 gene editing system targeting BMP2 delivery for bone healing and repair is proposed in this research.

Keywords: BMP2 gene editing, CRISPR/Cas9 technology, Nanocarriers, Bone regeneration, Osteoblasts

[This article belongs to International Journal of Advance in Molecular Engineering ]

How to cite this article:
Divya Saini. Nanocarrier-mediated CRISPR/Cas9 Gene Editing of BMP2 for Bone Repair. International Journal of Advance in Molecular Engineering. 2025; 03(01):14-21.
How to cite this URL:
Divya Saini. Nanocarrier-mediated CRISPR/Cas9 Gene Editing of BMP2 for Bone Repair. International Journal of Advance in Molecular Engineering. 2025; 03(01):14-21. Available from: https://journals.stmjournals.com/ijame/article=2025/view=198666


References

  1. Zhang, J., Zhao, Z., Pan, F., Li, H., & Wang, A. (2018). Nanocarrier-mediated bone morphogenetic protein 2 delivery for bone tissue engineering. Drug Delivery and Therapy, 10, 179–195.
  2. James, I. R., Udagawa, N., & Bonewald, L. F. (2021). Roles of bone morphogenetic protein (BMP)-2 in human bone repair and disease. Bone, 142, 107743.
  3. Li, X., Zhang, X., & Zhao, J. (2014). Preparation and evaluation of bone morphogenetic protein-2 loaded chitosan nanoparticles for bone regeneration. International journal of nanomedicine, 9, 4805–4814.
  4. Zhang, H., Wang, J., Lu, J., et al. (2020). Recent Advances in Nanocarriers for CRISPR/Cas9 Delivery. Journal of Drug Targeting, 28(7–8), 732–740.
  5. Zhang, J., Zhao, Z., Pan, F., Li, H., & Wang, A. (2018). Nanocarrier-mediated bone morphogenetic protein 2 delivery for bone tissue engineering. Drug Delivery and Therapy, 10, 179–195.
  6. Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., et al. (2013). Liposome: Classification, Preparation, and Applications. Nanoscale Research Letters, 8(1), 102
  7. Xu, X., Yang, J., Liu, H., et al. (2019). Challenges and Opportunities in CRISPR/Cas9 Delivery to Cells. Advanced Materials, 31(47), 1905741. doi: 10.1002/adma.201905741
  8. Li, J., Huang, L., Li, J., et al. (2020). Nanocarriers for CRISPR/Cas9 Delivery: Strategies and Challenges in Gene Editing for Therapeutic Applications. Nanomedicine (London, England), 15(23), 2277–2298.
  9. Chen, Y., Gao, D., Huang, L., et al. (2020). Recent Advances in CRISPR/Cas9 Delivery Strategies for Cancer Gene Therapy. Current Drug Metabolism, 21(7), 587–595.
  10. Gandhi, N. S., & Kang, S. E. (2018). Bone grafting for fracture healing. Orthopaedic clinics of North America, 49(4), 597–607.
  11. Wang, D., & Chen, H. (2022). Bone tissue engineering with gene-modified mesenchymal stem cells: A promising approach to bone regeneration.
  12. Wang, Y., Wang, G., Lv, X., et al. (2019). Nanotechnology-Mediated CRISPR-Cas9 Delivery for Genome Editing: Progress and Prospects. Biotechnology Advances, 37(4), 626–640.
  13. Massagué, J. (2012). TGFβ signalling in cancer. The Journal of Clinical Investigation, 122(2), 820–827.
  14. Zhang, X., Liu, X., Zhu, X., et al. (2020). CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Mesenchymal Stem Cells. Theranostics, 10(13), 5906–5925. doi: 10.7150/thno.44835
Regular Issue Subscription Review Article
Volume 03
Issue 01
Received 10/12/2024
Accepted 20/12/2024
Published 17/02/2025
Publication Time 69 Days
461

Login


My IP

PlumX Metrics